news
Our latest news, conferences we visit and papers we publish.
APO-T further strengthens its SAB with the addition of dr Michael Saunders and dr Torsten Dreier
OSS, NETHERLANDS – December 11th, 2019 – APO-T B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of dr Michael Saunders and dr Torsten Dreier.
Meet APO-T at Dutch Life Sciences Conference
APO-T B.V. will be present at Dutch Life Sciences Conference on 28th November 2019. To set up a meeting and learn more about APO-T technology contact dr Renier Heijkants at renier.heijkants@apo-t.com
Approval of Unique High Risk project proposal by KWF
Upon positive assessment of the KWF Unique High Risk project grant application APO-T and the group of dr Paul van Bergen en Henegouwen (UU) start collaboration on project…
APO-T to present its technology during 3rd Annual Next Gen Immuno-Oncology Congress
APO-T B.V. will present its technology during 3rd Annual Next Gen Immuno-Oncology Congress on 13th-14th March in London.
APO-T to join Innovation for Health
APO-T will join Innovation for Health on 14th February in Rotterdam. To set up a meeting and learn more about APO-T technology contact dr Marta Kijanka at marta.kijanka@apo-t.com
APO-T is selected to present its technology at Investors Forum during Dutch Life Sciences Conference
APO-T B.V. will present its technology during a pitch delivered at Investors Forum during Dutch Life Sciences Conference.
APO-T to present its technology during 6th Drug Discovery and Innovation Program
APO-T B.V. will present its technology during 6th Drug Discovery and Innovation Program on 30th November in Frankfurt.
New member of Scientific Advisory Board
Prof. Pierre van der Bruggen joins APO-T Scientific Advisory Board. Prof. van der Bruggen has identified the first human MAGE gen in 1991, coding for a tumor antigen recognized by cytolytic T lymphocytes.
APO-T to present its technology during BIO International Convention
APO-T B.V. will present its technology twice during BIO International Convention. Both presentations will take place on June 5th.
New member of Scientific Advisory Board
Dr Allard Kaptein joins APO-T Scientific Advisory Board. Dr Kaptein has over 20 years experience in pharmaceutical industry where he held several project and line management positions.
APO-T to present its technology during 2nd Annual Next Gen Immuno-Oncology Congress
APO-T B.V. will present its technology during 2nd Annual Next Gen Immuno-Oncology Congress on 13th-14th March in London.
APO-T to join 8th World ADC Europe Summit
APO-T B.V. will join 8th World ADC Europe Summit on 26th-28th March in Berlin. To set up a meeting and learn more about APO-T technology contact Erik Schooten at erik.schooten@apo-t.nl.
Approval of ZonMw grant application
Upon positive assessment of the ZonMw grant application APO-T and the group of prof. Judith Klumperman (UMCU) start collaboration on project entitled Advanced CLEM
APO-T appoints dr Marta Kijanka as acting CEO.
APO-T appoints dr Marta Kijanka as acting CEO, who previously held VP of RD position at APO-T.
APO-T selected to give an IDEA Pitch during Innovation for Health
APO-T has been selected to give an IDEA Pitch at the upcoming Innovation for Health on 1st February 2018 in WTC Rotterdam.